Quantcast

Lucintel Research Outlines Growth of Global Human Vaccine Industry

April 20, 2013

Lucintel Research Outlines Growth of Global Human Vaccine Industry

Irving, TX (PRWEB) April 20, 2013

The global vaccine industry comprises primarily human vaccine production. The annual revenue of this industry is forecast to reach an estimated $41.85 billion by 2018, with good growth over the next five years. Pfizer entered the top five player list in 2012 replacing Wyeth. Sanofi Aventis, Novartis AG, Merck Company, and GlaxoSmithKline are the other players in the top five players list.

Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the industry and presents its findings in “Global Human Vaccine Industry 2013-2018: Trend, Profit, and Forecast Analysis.” North America dominates this industry. India and China are rapidly growing as vaccine production hubs with strong domestic demand.

Lucintel’s report gives a brief overview of the industry challenges. The global human vaccine industry is currently growing at a double-digit rate although there are numerous challenges for the major players. Competitive rivalry is moderate to high in this industry, and the threat of new entrants is low due to high capital requirements and the comprehensive, rigorous approval process. In addition, these approval processes are a major challenge for the manufacturers due to their stringent rules. Developing vaccines for adult and pediatric diseases requires high research cost. Expiration of patents is another challenge faced by vaccine manufacturers.

Despite these challenges, the industry enjoys some strong drives, as the study highlights. The global economy is recovering after the recession, and increased incomes and lower cost of vaccines have helped more infants and children become immunized, especially in the Rest of the World and Asia Pacific regions. Various countries´ national immunization programs, effectively run by nongovernmental organizations such as WHO, UNICEF, and GAVI, are a key factor in fueling growth in the vaccine industry

This industry research report is an indispensable reference guide for vaccine manufacturers, researchers, people working with community health programs, investors, executives, distributors, and many more that operate in this market. To make business, investment, and strategic decisions, appropriate and useful information is needed, which is fulfilled by this market report.

For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk(at)lucintel(dot)com. Lucintel´s Opportunity Screening and Business Strategy Consulting services have supported decision makers in achieving their growth objectives.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10651279.htm


Source: prweb



comments powered by Disqus